Expression systems comprising nucleic acids encoding HIV-1 protease cleavage site polypeptides
US11813325B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 2, 2022 |
| Grant date | Nov 14, 2023 |
| Priority date | — |
| Expiry date | Jun 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.